Haemonetics Corporation

Haemonetics Corporation is a global medical technology company headquartered in Boston, Massachusetts, specializing in blood management, plasma collection, and vascular closure solutions for hospitals, blood centers, and plasma donation centers. The company develops innovative devices and software platforms that improve patient care quality, clinical outcomes, and operational efficiency across transfusion medicine and interventional procedures. Product portfolio includes blood collection and processing systems, plasma collection platforms, blood testing and safety solutions, and vascular closure devices. The company serves three primary market segments: hospitals (advancing surgical and critical care outcomes), blood centers (optimizing collection efficiency and blood component availability), and plasma centers (enhancing donor experience and collection yield). Haemonetics maintains FDA clearances and approvals for its portfolio, as evidenced by recent FDA approvals including expanded labeling for the VASCADE MVP® XL Venous Vascular Closure System and FDA clearance for the NexSys® PCS Plasma Collection System with Persona® PLUS Technology. The company is publicly traded and demonstrates commitment to regulatory compliance, operational excellence, and continuous innovation in transfusion medicine and interventional vascular technologies. Manufacturing and service capabilities span device production, software platforms, and customer support infrastructure.